Physician profile
Anna Leskiv
NPI 1770801920
$4,055.81
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $505 · 2021: $825 · 2022: $483 · 2023: $148 · 2024: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.49 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $758.92 | 2019-2021 | |
| Ucb, INC. | $567.67 | 2019-2023 | Nayzilam |
| Acadia Pharmaceuticals INC | $297.69 | 2019-2022 | |
| Neurelis, INC. | $281.83 | 2021-2022 | |
| Acorda Therapeutics, INC | $261.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $240.76 | 2019 | |
| Alexion Pharmaceuticals, INC. | $168.23 | 2019-2022 | |
| Amgen INC. | $149.90 | 2019 | |
| Abbvie INC. | $146.79 | 2021-2022 | |
| Djo, LLC | $140.62 | 2020 | |
| Neuropace, INC. | $138.91 | 2024 | |
| Sk Life Science, INC. | $125.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $110.60 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $80.17 | 2019 | |
| Amneal Pharmaceuticals LLC | $76.66 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $70.03 | 2019-2022 | |
| Lundbeck LLC | $52.62 | 2021-2022 | |
| Grifols USA, LLC | $49.01 | 2022-2023 | Xembify |
| Biohaven Pharmaceutical Holding Company LTD. | $47.57 | 2022 | |
| Ge Healthcare | $38.69 | 2019 | |
| Livanova USA, INC. | $36.65 | 2019 | |
| Genentech USA, INC. | $30.21 | 2019 | |
| Sunovion Pharmaceuticals INC. | $29.85 | 2019 | |
| Allergan, INC. | $27.57 | 2019-2021 | |
| Kyowa Kirin, INC. | $26.73 | 2022 | |
| Neurocrine Biosciences, INC. | $25.00 | 2020 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Bausch Health US, LLC | $17.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.63 | 2019 | |
| Lilly USA, LLC | $12.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Leskiv listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.